EyePoint Pharmaceuticals

Press Releases

pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences
Apr 01, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida's president and chief executive officer, Dr. Paul Ashton , will discuss pSivida's Tethadur™ technology
pSivida Announces Resubmission of New Drug Application for ILUVIEN®
Mar 27, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been
pSivida Corp. Announces $7.0 Million Investment by RA Capital
Mar 13, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest
pSivida Announces ILUVIEN® for DME Accepted by National Health Service Scotland
Feb 10, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use within the National Health
pSivida Corp. Reports Second Quarter 2014 Results
Feb 07, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013 .
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 12
Feb 06, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference ,
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11
Feb 06, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , President and CEO, will present at the 16 th Annual BioCEO & Investor Conference ,
pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information
Jan 30, 2014
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market
pSivida Corp. Reports First Orders for ILUVIEN® Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance
Jan 13, 2014
First NHS patient treated on January 10, 2014 WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial
pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN® for DME; Advisory Committee Meeting No Longer Necessary
Dec 18, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling discussions with the U.S.
pSivida Executives to Present at Two Upcoming Investor Conferences This Month
Dec 04, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor conferences: Lori Freedman , vice president
pSivida Reports ILUVIEN® to Be Funded by UK's National Health Service for Treatment of Pseudophakic Chronic DME Patients Following Issuance of Final NICE Guidance
Dec 02, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013 , the United Kingdom's National Institute for Health and Care Excellence (NICE)
pSivida Corp. Reports First Quarter 2014 Results
Nov 12, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its first quarter ended September 30, 2013 .
pSivida Corp Announces First Quarter 2014 Financial Results Release Date and Conference Call Information
Nov 05, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of fiscal year 2014 will be released after the
pSivida Reports Complete Response Letter From FDA for ILUVIEN®
Oct 18, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc.
pSivida Announces That U.K.'s NICE Recommends ILUVIEN® for Chronic Diabetic Macular Edema in Pseudophakic Eyes; NHS Reimbursement Expected to Follow
Sep 30, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Care
pSivida to Present at 4th Annual Conference on Biosimilars & Biobetters
Sep 27, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at the 4 th Annual Biosimilars & Biobetters Conference being held October 1 and 2 in
pSivida Corp. Reports Fourth Quarter and Fiscal Year 2013 Results
Sep 25, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2013 .
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial Results Release Date and Conference Call Information
Sep 18, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2013 will be released after the
pSivida to Present At Two Investment Conferences in September
Sep 04, 2013
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at two upcoming investor conferences in September.
Displaying 141 - 160 of 326
EyePoint Pharmaceuticals